Sex-based Differences in CEACAM5 Expression in Lung Cancer

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2024 Dec 19

PMID 39697744

Authors

Gavitt A Woodard

Emma R Kane

Nicholas Todorovic

Samantha Prince

Sanja Dacic

Lieping Chen

Affiliations

Soon will be listed here.

Abstract

Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is expressed in 20-25% of non-small cell lung cancer (NSCLC) and there is interest in CEACAM5 as a biomarker given its potential for blood-based detection and investigational study as a drug target. Increased expression of CEACAM5 has been observed in semi-solid lung adenocarcinoma lesions, which have an increased prevalence in women and never smokers. Given this association, sex-based differences in CEACAM5 were evaluated. The Cancer Genome Atlas (TCGA) data on CEACAM5 expression in NSCLC tumors (n=994) in women (n=398) and men (n=596) were analyzed for differences in expression of CEACAM5 based on sex and histologic subtypes of adenocarcinoma and for correlations with overall survival (OS). Among all stages of NSCLC, mean expression of CEACAM5 was 143.3 fragments per kilobase of transcript per million (FPKM) with differences observed between female and male patients (194.5 109.2 FPKM, P<0.0001) and between adenocarcinoma and squamous cell carcinoma (239.3 46.2 FPKM, P<0.0001). Differences persisted among combined sex and histology subgroups. High CEACAM5 was not predictive of survival in NSCLC or adenocarcinoma overall, but was associated with worse survival among stage I female patients with adenocarcinoma (5-year OS CEACAM5 high =33% low =64%, log-rank P=0.008). Higher levels of CEACAM5 expression are observed in NSCLC tumors in female patients and adenocarcinoma histology. High CEACAM5 expression in lung adenocarcinoma is associated with worse survival among female patients. The biologic impact of sex on CEACAM5 as a biomarker warrants further study.

References

Xu H, Zhao G, Lin J, Ye Q, Xiang J, Yan B . A combined preoperative red cell distribution width and carcinoembryonic antigen score contribute to prognosis prediction in stage I lung adenocarcinoma. World J Surg Oncol. 2023; 21(1):56. PMC: 9945661. DOI: 10.1186/s12957-023-02945-7. View

Mederos N, Friedlaender A, Peters S, Addeo A . Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer. ESMO Open. 2020; 5(Suppl 4):e000796. PMC: 7643520. DOI: 10.1136/esmoopen-2020-000796. View

Gazzah A, Bedard P, Hierro C, Kang Y, Abdul Razak A, Ryu M . Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022; 33(4):416-425. DOI: 10.1016/j.annonc.2021.12.012. View

Kim E, Cha Y, Lee S, Jeong S, Choi Y, Moon D . Early lung carcinogenesis and tumor microenvironment observed by single-cell transcriptome analysis. Transl Oncol. 2021; 15(1):101277. PMC: 8605359. DOI: 10.1016/j.tranon.2021.101277. View

Chlebowski R, Anderson G, Manson J, Schwartz A, Wakelee H, Gass M . Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J Natl Cancer Inst. 2010; 102(18):1413-21. PMC: 2943522. DOI: 10.1093/jnci/djq285. View

Lee J, Kim H, Shin B . Expression of female sex hormone receptors and its relation to clinicopathological characteristics and prognosis of lung adenocarcinoma. J Pathol Transl Med. 2019; 54(1):103-111. PMC: 6986970. DOI: 10.4132/jptm.2019.10.12. View

Hou X, Wu M, Chen J, Zhang R, Wang Y, Zhang S . Establishment and verification of a prediction model based on clinical characteristics and computed tomography radiomics parameters for distinguishing benign and malignant pulmonary nodules. J Thorac Dis. 2024; 16(3):1984-1995. PMC: 11009598. DOI: 10.21037/jtd-23-1400. View

Woodard G, Udelsman B, Prince S, Blasberg J, Dhanasopon A, Gange Jr C . Brief Report: Increasing Prevalence of Ground-Glass Nodules and Semisolid Lung Lesions on Outpatient Chest Computed Tomography Scans. JTO Clin Res Rep. 2023; 4(12):100583. PMC: 10709040. DOI: 10.1016/j.jtocrr.2023.100583. View

Hao C, Zhang G, Zhang L . Serum CEA levels in 49 different types of cancer and noncancer diseases. Prog Mol Biol Transl Sci. 2019; 162:213-227. DOI: 10.1016/bs.pmbts.2018.12.011. View

10.

Henschke C, Yankelevitz D, Reeves A, Yip R . Evolution of Lung Cancer Screening Management. Oncology (Williston Park). 2019; 33(7). View

11.

Lefebvre A, Adam J, Nicolazzi C, Larois C, Attenot F, Falda-Buscaiot F . The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape. Lung Cancer. 2023; 184:107356. DOI: 10.1016/j.lungcan.2023.107356. View

12.

Jemal A, Miller K, Ma J, Siegel R, Fedewa S, Islami F . Higher Lung Cancer Incidence in Young Women Than Young Men in the United States. N Engl J Med. 2018; 378(21):1999-2009. PMC: 7717174. DOI: 10.1056/NEJMoa1715907. View

13.

Azari F, Kennedy G, Chang A, Bernstein E, Nadeem B, Pelegrin A . Glycoprotein Receptor CEACAM5-Targeted Intraoperative Molecular Imaging Tracer in Non-Small Cell Lung Cancer. Ann Thorac Surg. 2022; 116(3):631-641. PMC: 9701246. DOI: 10.1016/j.athoracsur.2022.05.019. View

14.

Jiao Z, Cao S, Li J, Hu N, Gong Y, Wang L . Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome. Front Mol Biosci. 2021; 8:686313. PMC: 8578711. DOI: 10.3389/fmolb.2021.686313. View

15.

Dias M, Linhas R, Campainha S, Conde S, Barroso A . Lung cancer in never-smokers - what are the differences?. Acta Oncol. 2017; 56(7):931-935. DOI: 10.1080/0284186X.2017.1287944. View

16.

Ng K, King Sun C, Boom Ting K, Ting Kun A . Prognostic factors of EGFR-mutated metastatic adenocarcinoma of lung. Eur J Radiol. 2019; 123:108780. DOI: 10.1016/j.ejrad.2019.108780. View

17.

Woodard G, Ding V, Cho C, Brand N, Kratz J, Jones K . Comparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas. Lung Cancer. 2023; 180:107211. PMC: 10900430. DOI: 10.1016/j.lungcan.2023.107211. View

18.

Cai L, Lin S, Girard L, Zhou Y, Yang L, Ci B . LCE: an open web portal to explore gene expression and clinical associations in lung cancer. Oncogene. 2018; 38(14):2551-2564. PMC: 6477796. DOI: 10.1038/s41388-018-0588-2. View

19.

Izawa A, Hara Y, Horita N, Muraoka S, Kaneko M, Kaneko A . Improved diagnostic accuracy with three lung tumor markers compared to six-marker panel. Transl Lung Cancer Res. 2024; 13(3):503-511. PMC: 11002512. DOI: 10.21037/tlcr-23-855. View

20.

VINCENT R, Chu T, Fergen T, Ostrander M . Carcinoembryonic antigen in 228 patients with carcinoma of the lung. Cancer. 1975; 36(6):2069-76. DOI: 10.1002/cncr.2820360923. View